US drug maker Pfizer, which is developing a coronavirus vaccine with German pharma company BioNTech, has enrolled 42,113 volunteers for Phase II and Phase III clinical trials.
Pfizer has said it could file in late November for US authorization of the coronavirus vaccine it is developing, opening up the possibility of a vaccine being available in the United States by the end of the year.
No comments:
Post a Comment